1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014

Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 42 pages

Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Nerve Gas & Pestiside Poisioning - Pipeline Review, H1 2014’, provides an overview of the Nerve Gas & Pestiside Poisioning’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nerve Gas & Pestiside Poisioning
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Nerve Gas & Pestiside Poisioning and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Nerve Gas & Pestiside Poisioning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nerve Gas & Pestiside Poisioning pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nerve Gas & Pestiside Poisioning
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nerve Gas & Pestiside Poisioning pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Nerve Gas and Pestiside Poisioning - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nerve Gas and Pestiside Poisioning Overview 6
Therapeutics Development 7
Pipeline Products for Nerve Gas and Pestiside Poisioning - Overview 7
Pipeline Products for Nerve Gas and Pestiside Poisioning - Comparative Analysis 8
Nerve Gas and Pestiside Poisioning - Therapeutics under Development by Companies 9
Nerve Gas and Pestiside Poisioning - Therapeutics under Investigation by Universities/Institutes 10
Nerve Gas and Pestiside Poisioning - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Nerve Gas and Pestiside Poisioning - Products under Development by Companies 13
Nerve Gas and Pestiside Poisioning - Products under Investigation by Universities/Institutes 14
Nerve Gas and Pestiside Poisioning - Companies Involved in Therapeutics Development 15
Baxter International Inc. 15
PharmAthene, Inc. 16
Protalix BioTherapeutics, Inc. 17
MicroDose Therapeutx, Inc. 18
Nerve Gas and Pestiside Poisioning - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
MDT-010 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
PRX-105 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Plasma Derived Butyrylcholinesterase - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Second Generation Protexia - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Peptides for Nerve Gas and Pestiside Poisioning - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Nerve Gas and Pestiside Poisioning - Recent Pipeline Updates 34
Nerve Gas and Pestiside Poisioning - Dormant Projects 36
Nerve Gas and Pestiside Poisioning - Product Development Milestones 37
Featured News and Press Releases 37
Jun 11, 2013: Therapure Biopharma Receives Subcontract Award From DynPort For Development Of Anti-Nerve Gas Agent 37
May 23, 2013: AIBioTech Receives Subcontract Award From DynPort For Continued Development And FDA Approval Of Nerve Agent Prophylactic 37
May 09, 2013: DynPort Vaccine Receives US Army Contract Worth $156.6m To Develop Nerve Gas Prophylactic 38
Apr 17, 2013: PharmAthene's Recombinant Butyrylcholinesterase Successfully Targets Nerve Agents In In-Vitro Study 38
Oct 24, 2011: Aeolus Announces NIH Counteract Grant Award To Develop AEOL 10150 As Treatment Against Nerve Agent Exposure 39
Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables

Number of Products under Development for Nerve Gas and Pestiside Poisioning, H1 2014 7
Number of Products under Development for Nerve Gas and Pestiside Poisioning - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Nerve Gas and Pestiside Poisioning - Pipeline by Baxter International Inc., H1 2014 15
Nerve Gas and Pestiside Poisioning - Pipeline by PharmAthene, Inc., H1 2014 16
Nerve Gas and Pestiside Poisioning - Pipeline by Protalix BioTherapeutics, Inc., H1 2014 17
Nerve Gas and Pestiside Poisioning - Pipeline by MicroDose Therapeutx, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Nerve Gas and Pestiside Poisioning Therapeutics - Recent Pipeline Updates, H1 2014 34
Nerve Gas and Pestiside Poisioning - Dormant Projects, H1 2014 36

List of Figures

Number of Products under Development for Nerve Gas and Pestiside Poisioning, H1 2014 7
Number of Products under Development for Nerve Gas and Pestiside Poisioning - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.